Nuvectis Pharma has extended its August rally to nearly 24% on the week and 34% on the month — and options traders are now the most aggressively bullish they have been all year.
The options signal is the sharpest edge in this week's data. The put/call ratio collapsed to 0.034, almost two and a half standard deviations below its 20-day average of 0.085 — a reading near the floor of its 52-week range. That means call buying has swamped put demand to a degree that's statistically rare. It's a shift worth noting because it happened mid-week, as the stock accelerated through $25. Traders positioning via options are not hedging — they are leaning into the move.
Short interest tells a more complicated story, and the contrast matters. At 7% of the free float, the short book is still meaningful for a micro-cap biotech. It ticked up roughly 3% in a single session on August 25, and is slightly higher than a week ago — so shorts have not been decisively squeezed out of the move. The ORTEX short score has sat in a tight band around 69 all month, reflecting that mix of elevated short positioning and building momentum without a clean resolution in either direction. Borrow availability has eased slightly to around 48% — tighter than the broader August range but well off the lows below 22% seen in late July. Cost to borrow has fallen sharply, now under 1.6%, roughly half the level from a month ago. That makes it cheaper and marginally easier to add short exposure, which may explain why the short count isn't collapsing even as the stock runs.
The Street has been warming to the name in stages. Cantor Fitzgerald initiated coverage with an Overweight rating on August 24 — the freshest signal on record and notable as a new voice entering the story. Roth Capital raised its target from $20 to $33 in early July. HC Wainwright has a $39 target in place. With the stock at $25.89, the consensus implies meaningful further upside, though the bear case centres on pipeline execution risk: limited efficacy data from NXP800 and NXP900 trials, potential drug-drug interactions in the combination strategy, and the perpetual cash runway question that haunts clinical-stage names without revenue. The analyst recommendation score ranks in the 92nd percentile — bulls are well-represented on the Street, but there are only four buy ratings, so the consensus is shallow and fragile.
The institutional ownership picture, consistent with the note published earlier this week, remains the structural underpinning of the rally. Tang Capital, Soleus Capital, and Perceptive Advisors all opened new positions in Q2, collectively adding close to 4 million shares into a float of roughly 25 million. The CEO and founder Ron Bentsur bought 12,500 shares at $20 in June, and 10% shareholder Charles Mosseri-Marlio added 50,000 shares at $18.32 in the same month. That cluster of insider and specialist-fund buying at prices well below current levels gives the move a foundation beyond pure momentum — though it also means those buyers are now sitting on material gains and represent potential supply.
Peer performance this week puts NVCT's move in relief: GALT gained 13% and KRYS and RCUS added around 7%, so the broader small-cap biotech tape has been constructive — but NVCT has outrun the peer group by a wide margin. The next scheduled catalyst is the November 5 earnings date. Between now and then, the key variables are whether the short book begins to compress as the stock holds above $25, and whether any clinical or business development news arrives to give institutional buyers a fresh anchor.
See the live data behind this article on ORTEX.
Open NVCT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
